HSP90 inhibitor SNX5422/2112 targets the dysregulated signal and transcription factor network and malignant phenotype of head and neck squamous cell carcinoma

Translational Oncology

Volumn 6, Issue 4, 2013, Pages 429-441

  Friedman, Jay A ^a   Wise, Stephanie C ^a   Hu, Michael ^a   Gouveia, Chris ^a   Vander Broek, Robert ^a   Freudlsperger, Christian ^a,b   Kannabiran, Vishnu R ^a   Arun, Pattatheyil ^a   Mitchell, James B ^c   Chen, Zhong ^a   Van Waes, Carter ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PIFITHRIN ALPHA; PLACEBO; PROTEIN P53; PUMA PROTEIN; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; SNX 2112; SNX 5422; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HEAD AND NECK SQUAMOUS CLL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR XENOGRAFT; VIRUS ONCOGENE; WESTERN BLOTTING;

EID: 84881083529     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13292     Document Type: Article

References (63)

1. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354, 567-578.
2. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al. (2008). Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359, 1116-1127.
3. Egloff AM and Grandis JR (2008). Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol 35, 286-297.
4. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, and Vokes EE (2009). Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol 45, e155-e160.
5. Van Waes C, Allen CT, Citrin D, Gius D, Colevas AD, Harold NA, Rudy S, Nottingham L, Muir C, Chen Z, et al. (2010). Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 77, 447-454.
6. Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, et al. (2005). Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63, 1400-1412.
7. Allen C, Saigal K, Nottingham L, Arun P, Chen Z, and Van Waes C (2008). Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-κB subunits in head and neck cancer. Clin Cancer Res 14, 4175-4185.
8. Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, et al. (2012). First-in-human trial of a STAT3 decoy oligo-nucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov 2, 694-705.
9. Clayman GL (2000). The current status of gene therapy. Semin Oncol 27, 39-43.
10. Wang F, Arun P, Friedman J, Chen Z, and Van Waes C (2009). Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol 9, 389-395.
11. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, et al. (2009). The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69, 3021-3031.
12. Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, Dabir B, Saigal K, Mundinger GS, Xu X, Morris JC, et al. (2009). Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 15, 2361-2372.
13. Friedman J, Nottingham L, Duggal P, Pernas FG, Yan B, Yang XP, Chen Z, and Van Waes C (2007). Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Clin Cancer Res 13, 6568-6578.
14. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG, and Carey TE (2003). P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25, 654-661.
15. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, et al. (2007). TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357, 2552-2561.
16. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, et al. (2011). The mutational landscape of head and neck squamous cell carcinoma. Science 333, 157-1160.
17. Grandis JR, Hayes DN, and El-aggar A, and The Cancer Genome Atlas Group (2012). Comprehensive genomic characterization of squamous cell carcinoma of the head and neck. In TCGA 2nd Annual Scientific Symposium. p. 32.
18. Boehm AL, Sen M, Seethala R, Goodling WE, Freilino M, Wong SM, Wang S, Johnson DE, and Grandis JR (2008). Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-XL enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol 73, 1632-1642.
19. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, and Harari PM (2009). Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 15, 1585-1592.
20. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, et al. (2009). PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colo-rectal cancer patients. Ann Oncol 20, 84-90.
21. Tortora G, Ciardiello F, and Gasparini G (2008). Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 5, 521-530.
22. Lee TL, Yeh J, Friedman J, Yan B, Yang X, Yeh NT, Van Waes C, and Chen Z (2008). A signal network involving coactivated NF-κB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 122, 1987-1998.
23. Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT, and Van Waes C (2008). Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms. Mol Cancer Ther 7, 1949-1960.
24. Miyata Y, Nakamoto H, and Neckers L (2013). The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des 19, 347-365.
25. Zhang H and Burrows F (2004). Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82, 488-499.
26. Trepel J, Mollapour M, Giaccone G, and Neckers L (2010). Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10, 537-549.
27. Caraglia M, Abbruzze A, Leardi A, Pepe S, Budillon A, Baldassare G, Selleri C, Lorenzo SD, Fabbrocini A, Giuberti G, et al. (1999). Interferon-α induces apop-tosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ 6, 773-780.
28. Nyati MK, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB, Gouveia C, Truong K, Van Waes C, Ray D, et al. (2012). Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia 14, 670-677.
29. Misso G, Giuberti G, Lombardi A, Grimaldi A, Ricciardiello F, Giordano A, Tagliaferri P, Abbruzzese A, and Caraglia M (2013). Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC. J Cell Physiol 228, 130-141.
30. Yin X, Zhang H, Burrows F, Zhang L, and Shores CG (2005). Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 11, 3889-3896.
31. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, and Shores CG (2010). BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer 126, 1216-1225.
32. Huang KH, Veal JM, Fadden RP, Rice JW, Eaves J, Strachan JP, Barabasz AF, Foley BE, Barta TE, Ma W, et al. (2009). Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 52, 4288-4305.
33. Fadden P, Huang KH, Veal JM, Steed PM, Barabasz AF, Foley B, Hu M, Partridge JM, Rice J, Scott A, et al. (2010). Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting Hsp90. Chem Biol 17, 686-694.
34. Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, et al. (2009). SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113, 846-855.
35. Rice JW, Veal JM, Barabasz A, Foley B, Fadden P, Scott A, Huang K, Steed P, and Hall S (2009). Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib. Oncol Res 18, 229-242.
36. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, et al. (2008). SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14, 240-248.
37. Bachleitner-Hofmann T, Sun MY, Chen CT, Liska D, Zeng Z, Viale A, Olshen AB, Mittlboeck M, Christensen JG, Rosen N, et al. (2011). Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition. Clin Cancer Res 17, 122-133.
38. Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, et al. (2011). A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 17, 6831-6839.
39. Infante JR, Weiss GJ, Jones S, Tibes R, Bendell JC, Brega N, Torti V, Von Hoff DD, Buris HA, and Ramanathan R (2010). A phase I dose escalation study of the oral heat shock protein 90 inhibitor PF-04929113 (SNX5422) and its associated ocular toxicity. In 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. p. 375.
40. Bauer TM, Infante JR, Ramanathan RK, Weiss GJ, Sachdev J, Burris HA, Hinson JM, and Orlemans EO (2013). Results of two phase 1 dose escalation studies of the oral heat shock protein 90 (Hsp90) inhibitor SNX-5422. Am Soc Clin Oncol 2013, 117030.
41. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, Bradford CR, and Carey TE (2010). Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 32, 417-426.
42. Yan B, Yang X, Lee TL, Friedman J, Tang J, Van Waes C, and Chen Z (2007). Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-κB and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol 8, R78.
43. Lee TL, Yang XP, Yan B, Friedman J, Duggal P, Bagain L, Dong G, Yeh NT, Wang J, Zhou J, et al. (2007). A novel nuclear factor-κB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 13, 5680-5691.
44. Arun P, Brown MS, Ehsanian R, Chen Z, and Van Waes C (2009). Nuclear NF-κB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer. Clin Cancer Res 15, 5974-5984.
45. Kato T, Duffey DC, Ondrey FG, Dong G, Chen Z, Cook JA, Mitchell JB, and Van Waes C (2000). Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-κB. Head Neck 22, 748-759.
46. Allen C, Duffy S, Teknos T, Islam M, Chen Z, Albert PS, Wolf G, and Van Waes C (2007). Nuclear factor-κB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 13, 3182-3190.
47. Ito T, Kawabe R, Kurasono Y, Hara M, Kitamura H, Fujita K, and Kanisawa M (1998). Expression of heat shock proteins in squamous cell carcinoma of the tongue: an immunohistochemical study. J Oral Pathol Med 27, 18-22.
48. Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, and Van Waes C (2011). EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets 15, 63-74.
49. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, and Van Waes C (2001). Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61, 5911-5918.
50. Lee TL, Yeh J, Van Waes C, and Chen Z (2006). Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 5, 8-19.
51. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C, and Van Waes C (2002). Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99, 538-548.
52. Bancroft CC, Chen Z, Dong G, Sunwoo JB, Yeh N, Park C, and Van Waes C (2001). Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kB signal pathways. Clin Cancer Res 7, 435-442.
53. Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE, Yeh NT, Mukaida N, and Van Waes C (2001). IL (interleukin)-1a promotes nuclear factor-KB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 7, 1812-1820.
54. Mayo LD and Donner DB (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl AcadSci USA 98, 11598-11603.
55. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, and Gurova KV (2009). 9-Aminoacridine-based anticancer drugs target the PI3K/ AKT/mTOR, NF-kB and p53 pathways. Oncogene 28, 1151-1161.
56. Sasaki M, Nie L, and Maki CG (2007). MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J Biol Chem 282, 14626-14634.
57. Peng Y, Chen L, Li C, Lu W, and Chen J (2001). Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 276, 40583-40590.
58. Sawarkar R, Sievers C, and Paro R (2012). Hsp90 globally targets paused RNA polymerase to regulate gene expression in response to environmental stimuli. Cell 149, 807-818.
59. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, and Neckers L (1995). Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 55, 4623-4626.
60. Sen T, Chang X, Sidransky D, and Chatterjee A (2010). Regulation of ANp63oc by NFkÂ. Cell Cycle 9, 4841-4847.
61. Lu H, Yang X, Duggal P, Allen CT, Yan B, Cohen J, Nottingham L, Romano RA, Sinha S, King KE, et al. (2011). TNF-a promotes c-REL/ANp63a interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer. Cancer Res 71, 6867-6877.
62. Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, et al. (2010). Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 46, 340-347.
63. Riely GJ, Gettinger SN, Stoller RG, Gabrail NY, Dy GK, Weiss GJ, Tunkey C, Skliris G, Strychor S, Dunbar J, et al. (2011). Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 9, 2011(suppl; abstr 7516).